iPSC colony.png




AND...Identifying the

Cornerstones for Disease Modification

  • Universal Approach / "Rescue Therapy"

  • Individual Approach / "Cure"

JANUARY 27, 2021  |  Time: 3:00pm-5:00pm PST


Please NOTE: Subject to Change


2020-11-09 (12).png

Download pdf -

Click flyer image


WHERE ARE RESEARCHERS? AND...Identifying the Cornerstones for Disease Modification

  • Universal Approach / “Rescue Therapy”

  • Individual Approach / “Cure”

Time: 3:00-5:00pm PST

January 27, 2021

Featured Guest Speaker: 

Alberto Espay, M.D., MSc, FAAN, FANA

Disease modification - A look the argument in favor of

(1) an universal approach of soluble protein replacement as “rescue” therapy and

(2) an individualized approach targeting the molecular biology of individuals, as a true “cure”.

The latter category cannot be universalized because PD (as it is the case with other clinicopathologic labels, such as AD, FTD, DLB, etc.) is not one disease –and syndromes cannot be cured.

Registration: OPEN NOW

Cost:  $35.00

MDs, PAs & RNs: 2 - Category 1 CME credits

Sponsored by, The Seim Family and funded, in part,

by a grant from the San Diego County Board of Supervisors.


A live webinar with 

moderated presentations from our featured guest speakers, followed by a Q&A discussion.


Jeanne Loring, Ph.D.,


Director & Chief Science Officer, Summit for Stem Cell Foundation.

Professor, Scripps Research Institute

Founder, Aspen Neuroscience

Jeanne F. Loring is the Professor Emeritus at the Scripps Research Institute where she was founding Director of the Center for Regenerative Medicine. She is also founder of two stem cell-based biotechnology companies, Arcos Bioscience (now part of Viacyte) and Aspen Neuroscience, a biotechnology company developing a neuron replacement therapy for Parkinson disease.  Dr. Loring has more than 30 years of experience in both biotechnology and academic research, focusing on stem cells, genomics, embryology and neurobiology. She holds five patents on stem cells and genomics, and has published more than 100 research articles in scientific journals that have been cited in scientific publications more than 14,000 times. She serves on both scientific advisory and bioethics boards, and advises governmental and private granting agencies in several countries. Through her laboratory courses, she has trained more than 400 scientists in stem cell technology.

In addition to her work on Parkinson disease, Dr. Loring investigates multiple sclerosis and autism, and works with the San Diego Zoo Institute for Conservation Research in an effort to rescue the Northern white rhinoceros from extinction using stem cell technology.  She is also involved in a project on the International Space Station to study neurogenerative disease.

Dr. Loring is an advocate for patients and an outspoken critic of stem cell clinics that operate outside of ethical or scientific oversight. She speaks out against unregulated stem cell therapies that have  caused severe injuries and even death, and the clinics who convince desperately ill patients to pay for treatments that are not effective.

Alberto Espay, MD, MSc, FAAN, FANA

Featured Guest Speaker

About Dr. Alberto Espay

Dr. Alberto Espay, is professor and endowed chair of the University of Cincinnati James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders. He trained in neurology at Indiana University as well as in clinical and electrophysiology of movement disorders at the University of Toronto, where he obtained a master’s degree in clinical epidemiology and healthcare research.

 He has published over 250 research articles as well as 7 textbooks, including Common Movement Disorders Pitfalls, which received the Highly Commended BMA Medical Book Award in 2013. His most recent book Brain Fables, the Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer them, was coauthored with Parkinson patient and advocate Ben Stecher and published by Cambridge in August. He has served as Chair of the Movement Disorders Section of the American Academy of Neurology, Associate Editor of Movement Disorders, and in the Executive Committee of the Parkinson Study Group (PSG). He currently serves the International Parkinson and Movement Disorders Society (MDS) as Chair of the Task Force on Technology and as Secretary of its Pan-American Section.


About Dr. Espay's Research

The Cincinnati Cohort Biomarker Program* (CCBP) embraces the idea that there are likely dozens of biological pathways that lead to neurodegenerative diseases and that we must find and target each separately if we are ever going to get therapies that can alter these diseases in the individuals affected. The purpose of CCBP is to separate neurodegenerative diseases into their biological subtypes and then match each to therapies capable of slowing disease progression. In the first 5 years, the program will recruit 5000 people (4000 patients and 1000 healthy controls). Subsequent analysis will be anchored on bioassays selected to match people to existing therapies.

*Summit for Stem Cell Foundation provides funding and support for this research program.

Rita Ceponiene, MD, PhD


Director, Summit for Stem Cell Foundation

Dr. Ceponiene is American Board of Psychiatry and Neurology certified member of the American Academy of Neurology and the Movement Disorders Society, with a PhD in Cognitive Neuroscience at the Helsinki University, Finland. She has published over 40 peer – reviewed research articles during her academic career. Dr. Ceponiene has since returned to clinical work currently is a movement disorders specialist at Southern California Kaiser Permanente, San Diego. She continues to maintain ties with her academic colleagues and is passionate about educating patients and health care providers about the developments in the field. One of them is the promise of the autologous dopamine neuron replacement therapy that is being developed within a rigorous scientific framework.

Abigail Lawler, M.D.


Director/Medical Advisor, Summit for Stem Cell Foundation

Dr. Lawler is a board-certified member of the American Board of Psychiatry and Neurology and is a member of the American Academy of Neurology and the Movement Disorders Society. Dr. Lawler is originally from Ohio where she completed undergrad at Ohio University and also studied abroad through Duke University in Costa Rica where she completed a Spanish immersion program. She came back to Ohio for medical school at University of Toledo and then went on to complete her residency training in neurology at Medstar Georgetown University Hospital in Washington D.C., where she served as chief resident. Dr. Lawler stayed at Georgetown University to complete a fellowship in Movement and Memory Disorders at the highly acclaimed Translational Neurotherapeutics Program where she was extensively involved in clinical research, including the pivotal ongoing study using Nilotinib for treatment of Parkinson's Disease and Alzheimer's Disease, helped start the first ever Parkinsonism and Dementia clinic, and participated in baseline cognitive and neurologic assessments of retired NFL players for the NFL Players association. Dr. Lawler has published a variety of papers and posters on topics involving the use of Nilotinib in the treatment of Parkinson's Disease and Lewy Body Disease. Dr. Lawler is experienced in treating many different neurologic conditions but specializes in the diagnosis and treatment of Movement Disorders, offering a wide variety of treatment options beyond traditional medical management for Parkinson's Disease including programming and management of Deep Brain Stimulation and the Duopa LCIG infusion pump. Dr. Lawler also specializes in the diagnosis and treatment of a variety of Autonomic conditions, muscle dystonia and spasticity using Botulinum toxin injections, as well as all of the various types of Dementia. Dr. Lawler is very passionate about the care and treatment of patients with memory disorders and plans to start a new program and center of excellence with the goal of not only improving patient care and treatment options but starting a nationwide campaign of awareness.